Bluejay Diagnostics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Bluejay Diagnostics, Inc. (BJDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $10.60 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-03-28
- Bluejay Diagnostics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.53, a 71.81% decline year-over-year.
- Bluejay Diagnostics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.88.
- Bluejay Diagnostics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.60, a 488.89% increase from fiscal 2022.
- Bluejay Diagnostics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.80, a 44.62% decline from fiscal 2021.
- Bluejay Diagnostics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $3.25.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2023-12-31 | $10.60 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $10.60 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $10.60 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $0.53 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $1.80 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $1.84 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $1.84 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $1.88 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $3.25 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $3.50 10-Q · filed 2021-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |